What Is Claimed Is:

5

10

io La

1 20

30

- 1. A method of inducing a reduced immune response to donor tissue in a transplant recipient, comprising treating the recipient with at least one member selected from the group consisting of fibroblasts and a supernatant from a fibroblast culture in an amount effective to reduce an immune response in the recipient to the transplanted donor tissue.
 - 2. The method of claim 1 wherein said at least one member is fibroblasts.
 - 3. The method of claim 2 wherein the fibroblasts are autologous to the recipient.
 - 4. The method of claim 2 wherein the fibroblasts are allogeneic to the recipient.
- 5. The method of claim 4, wherein the fibroblasts are obtained from the donor of the transplant.
- 6. The method of claim 2 wherein the fibroblasts are allogeneic to both the donor of the transplant and the recipient.
- 7. The method of claim 2, wherein the fibroblasts are administered to the recipient prior to administration of the transplant.
- 8. The method of claim 2, wherein the fibroblasts are administered concurrently with administration of the transplant.
- 9. The method of claim 8, wherein the fibroblasts are administered as a part of the transplant.
 - 10. The method of claim 2 wherein the fibroblasts are administered after transplant.
 - 11. The method of claim 2 wherein the fibroblasts are administered to the transplant recipient to treat rejection of the transplant by the recipient.
 - 12. The method of claim 2, wherein the fibroblasts are human.

5

10

Then 50 m years of the 15 and 15 and

25

30

- 13. The method of claim 1, further comprising administering to the recipient immunosuppressive agents.
 - 14. The method of claim 1 wherein the donor tissue is a solid organ.
- 15. The method of claim 14 wherein the solid organ is selected from heart, kidney, lung or liver.
- 16. A method of reducing an immune response against recipient tissue by donor tissue, comprising contacting the donor tissue with at least one member selected from the group consisting of fibroblasts and a supernatant from a fibroblast culture in an amount effective to reduce an immune response by the donor tissue against the recipient.
 - 17. The method of claim 16 wherein said at least one member is fibroblasts.
 - 18. The method of claim 17, wherein the fibroblasts are autologous to the recipient.
 - 19. The method of claim 17, wherein the fibroblasts are autologous to the donor.
- 20. The method of claim 17, wherein the fibroblasts are allogeneic both to the donor and to the recipient of the donor tissue.
- 21. The method of claim 17, wherein the donor tissue and the fibroblasts are contacted ex vivo prior to transplantation of the donor tissue.
 - 22. The method of claim 21, wherein the donor tissue is exposed to recipient tissue prior to being contacted with the fibroblasts.
 - 23. The method of claim 18 wherein the fibroblasts are obtained from the recipient.
 - 24. The method of claim 16 wherein the donor tissue is bone marrow.

25. The method of claim 16 wherein the donor tissue is peripheral blood.

...**5**

10

- 26. The method of claim 16, further comprising administering to the recipient immunosuppressive agents.
- 27. A method of treating a transplant recipient for graft versus host disease, comprising treating the recipient of a transplant with at least one member selected from the group consisting of fibroblasts and a supernatant from a fibroblast culture in an amount effective to reduce an immune response against the recipient by the transplanted donor tissue.
 - 28. The method of claim 27 wherein said at least one member is fibroblasts.
 - 29. The method of claim 28, wherein the fibroblasts are autologous to the recipient.
 - 30. The method of claim 28, wherein the fibroblasts are autologous to the donor.
- 31. The method of claim 28, wherein the fibroblasts are allogeneic to both the donor and recipient.
- 32. The method of claim 27, further comprising administering to the recipient immunosuppressive agents.
- 33. A composition for treating an adverse immune response, comprising human fibroblasts in an amount effective to inhibit or reduce an adverse immune response to donor
 25 tissue in a transplant recipient, and a pharmaceutical carrier.